Alnylam posts Q3 2026 results, widens nucresiran trial, advances Huntington's programOct 29Quarterly updateAlnylam Pharmaceuticalsnucresiran
Kiniksa raises 2026 ARCALYST sales guidance, confirms KPL-387 data timingOct 27Regulatory decisionAlvotechFirst Tracks Biotherapeutics, Inc.Updated
Kiniksa raises 2026 ARCALYST guidance, advances KPL-387 into Phase 3 pericarditis trialJul 28Quarterly updateKiniksa Pharmaceuticals International, plcKPL-387